Drug intelligence / Profile preview

CLS974

Development stage: Preclinical
Lead developer: Cellusion
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Ophthalmic

Overview

CLS974 is a research-stage cell therapy candidate being developed by Cellusion in collaboration with Keio University. It is based on the company's proprietary FRiEND Tech (Function-added Regenerative iPSC-derived ENdothelial cell Technology) platform, which enables the creation of 'Function Added CECSi Cells.' These are induced pluripotent stem cell (iPSC)-derived endothelial cells that have been genetically or functionally modified to perform specific therapeutic roles. CLS974 is currently being investigated for its potential in treating retinal diseases and oncology, where the modified cells may act as delivery vehicles for therapeutic agents or provide direct regenerative and anti-tumor effects within the target tissue microenvironment.

Beyond the preview

Go deeper on CLS974.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLS974.

Explore the full profile